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MESSAGE FROM THE ASSISTANT SECRETARY
FOR MENTAL HEALTH AND SUBSTANCE USE, 
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
As the first U.S. Department of Health and Human Services Assistant Secretary for Mental Health and 
Substance Use at the Substance Abuse and Mental Health Services Administration (SAMHSA), I am pleased 
to present this new resource: Treatment of Stimulant Use Disorders. In response to the charge of the 21st 
Century Cures Act to disseminate information on evidence-based practices and service delivery models, the 
National Mental Health and Substance Use Policy Lab has developed the Evidence-Based Resource Guide 
Series focused on the prevention and treatment of substance use disorders and mental illnesses. With this guide, 
SAMHSA’s goal is to inform health care providers, healthcare administrators, policy makers, and community 
members of the rising rates of stimulant use and the need for targeted treatment programs and practices.
Stimulant use is on the rise in the United States. According to the 2018 National Survey on Drug Use and 
Health, an estimated 5.1 million people aged 12 or older misused prescription stimulants in the past year; 
approximately 1.9 million people aged 12 or older used methamphetamine in the past year with significant 
increases in use in those aged 26 and older; and 5.5 million people aged 12 or older used cocaine in the past 
year.1 Overdose deaths linked to psychostimulants increased approximately 22 percent from 2017 to 2018 and 
have increased more than three fold over the past five years. Deaths from cocaine, which can be laced with 
fentanyl, increased by 5 percent from 2017 to 2018 and are more than double what they were in 2015.2 The 
combination of all types of stimulants with unknown amounts of fentanyl increases the risk of overdose and 
overdose death substantially.3
This guide discusses effective practices to treat stimulant use disorders, clinical challenges associated with these 
disorders, and implementation strategies that can be used to address those challenges. I encourage you to use 
this guide to identify treatment practices you can implement to address stimulant use in your healthcare settings 
and communities.
Elinore F. McCance-Katz, MD, PhD  
Assistant Secretary for Mental Health and Substance Use 
U.S. Department of Health and Human Services
1 Substance Abuse and Mental Health Services Administration. (2019). Key substance use and mental health indicators in the 
United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH 
Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services 
Administration. Retrieved from https://www.samhsa.gov/data/. 
2  National Institute on Drug Abuse. (2019). Overdose death rates. Retrieved from https://www.drugabuse.gov/related-topics/
trends-statistics/overdose-death-rates
3  National Institute on Drug Abuse. (2019). DrugFacts: What is fentanyl? Retrieved from https://www.drugabuse.gov/publications/
drugfacts/fentanyl
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FOREWORD
Evidence-Based Resource Guide 
Series Overview
The Substance Abuse and Mental Health Services 
Administration (SAMHSA), and specifically, its National 
Mental Health and Substance Use Policy Laboratory 
(Policy Lab), is pleased to fulfill the charge of the 
21st Century Cures Act to disseminate information on 
evidence-based practices and service delivery models to 
prevent substance misuse and help people with substance 
use disorders (SUD), serious mental illnesses (SMI), and 
serious emotional disturbances (SED) get the treatment 
and support they need.
Treatment and recovery for SUD, SMI, and SED can 
vary based on a number of geographic, socio-economic, 
cultural, gender, race, ethnicity, and age-related factors 
which can complicate evaluating the effectiveness 
of services, treatments, and supports. Despite these 
variations, however, there is substantial evidence to 
inform the types of resources that can help reduce 
substance use, lessen symptoms of mental illness, and 
improve quality of life. 
The Evidence-Based Resource Guide Series is a 
comprehensive set of modules with resources to improve 
health outcomes for people at risk for, with, or recovering 
from mental and/or substance use disorders. It is designed 
for practitioners, administrators, community leaders, and 
others considering an intervention for their organization or 
community. A priority topic for SAMHSA is encouraging 
practices that reduce stimulant use, lower the risk of 
overdose, and promote recovery from stimulant use 
disorders. This guide reviews the literature and science, 
examines evidence-based practices, determines key 
components of those practices, identifies challenges and 
strategies for implementation, and discusses evaluation 
of implemented evidence-based practices. The purpose 
of this document is to identify potential treatment 
strategies and evidence-based practices for stimulant use 
disorders and does not include all resources required for 
implementation of those practices. 
Expert panels of federal, state, and non-governmental 
participants provide input for each guide in this series. 
The panels include accomplished scientists, researchers, 
service providers, community administrators, federal and 
state policy makers, and people with lived experience. 
Members provide input based on their knowledge of 
healthcare systems, implementation strategies, evidence-
based practices, provision of services, and policies that 
foster change. 
Research shows that implementing evidence-based 
practices requires a comprehensive, multi-pronged 
approach. This guide is one piece of an overall approach 
to implement and sustain change. Readers are encouraged 
to visit the SAMHSA website for additional tools and 
technical assistance opportunities.
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Content of the Guide
This guide contains a foreword and five chapters. The chapters are meant to 
stand alone and do not need to be read in order. Each chapter is designed to be 
brief and accessible to healthcare providers, healthcare system administrators, 
community members, policy makers, and others working to meet the needs of 
people at risk for, experiencing, or recovering from mental and/or substance use 
disorders. The goal of this guide is to review the literature on treating stimulant 
use disorders, distill the research into recommendations for practice, and provide 
examples of how practitioners use these practices in their programs.  1 
FW Evidence-Based Resource Guide Series 
Overview
Introduction to the series.
1 Issue Brief
Overview of current approaches and challenges to 
addressing stimulant use disorders in communities. 
2 What Research Tells Us
Current evidence on effectiveness of the following practices 
included in the guide to address stimulant use disorders: 
Motivational Interviewing, Contingency Management, 
Community Reinforcement Approach, and Cognitive 
Behavioral Therapy.
3 Guidance for Selecting and Implementing 
Evidence-based Practices
Practical information to consider when selecting and 
implementing practices to address stimulant use disorders.
4 Examples of Stimulant Use Treatment Programs
Descriptions of programs that use practices from Chapter 2 
to address stimulant use disorders.
5 Resources for Evaluation and Quality 
Improvement
Guidance and resources for implementing best practices, 
monitoring outcomes, and improving quality.
FOCUS OF THE GUIDE
Stimulant use is rising and becoming 
a public health crisis similar to the 
opioid epidemic. Illicit stimulants, 
like cocaine and amphetamines, 
are more accessible and have 
evolved to be purer, cheaper, and 
more potent. Stimulants are harmful 
to the cardiovascular system and 
can cause lung and brain diseases, 
stroke, and even death. 
Treating addiction to stimulants is 
critical, but especially challenging. 
Unlike opioids, there is no FDA-
approved medication currently 
available for stimulant use disorders. 
People who misuse opioids—
which suppress the functioning of 
the central nervous system—and 
stimulants in combination, often do 
so to reverse or modulate the effect 
of the other.1
This guide presents four evidence-
based programs and practices that 
address treatment of stimulant use. 
It supports SAMHSA’s Strategic Plan 
Objective 3.4 to: 
“Support the identification and 
adoption of evidence-based 
practices, programs, and policies 
that prevent substance use, increase 
provision of substance use disorders 
treatment, and enable individuals to 
achieve long-term recovery.” 
This guide covers cocaine and 
amphetamine-type stimulants that 
increase alertness and energy; 
heighten arousal; elevate blood 
pressure, heart rate, and respiration; 
and cause behavioral excitement. 
The guide also recognizes the 
misuse of prescription stimulants, 
such as dextroamphetamine 
and methylphenidate, found in 
medications used for conditions 
like attention-deficit hyperactivity 
disorder (ADHD), narcolepsy, and 
depression.
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The framework below provides an overview of this guide. The guide addresses stimulant use disorders, including illicit and 
prescription stimulants. The focus of the guide is on treatment practices that have been evaluated with adults. The review 
of these interventions in Chapter 2 of the guide includes specific outcomes, practitioner types, and delivery settings for the 
practices.





This chapter presents an overview of stimulant use 
disorders, specifically focusing on its prevalence in the 
population and its impact on individuals and society. 
Stimulant use disorders include a range of problems 
associated with the use of methamphetamine, cocaine, and 
other amphetamines. Diagnosis of a stimulant disorder is 
based on the occurrence of at least two of the following 
within a 12 month period.2
•	 Taking more stimulants than intended
•	 Failing to cut down or control use of stimulants, 
despite wanting to do so
•	 Spending excessive amounts of time in activities 
surrounding stimulant use
•	 Experiencing urges and cravings for stimulants
•	 Failing to meet the obligations of home, school, 
or work
•	 Continuing to take stimulants, even if it has led 
to relationship or social problems
•	 Giving up or reducing important recreational, 
social, or work-related activities because of 
stimulant use
•	 Using stimulants in situations in which it is 
physically hazardous
•	 Continuing to use stimulants even if there is 
an awareness that it is causing or worsening a 
physical or psychological problem
•	 Experiencing an increase in tolerance to 
stimulants
•	 Having withdrawal symptoms when not taken
Misuse of prescription stimulants and abuse of illicit 
stimulants, such as cocaine and amphetamines, continues 
to rise in the United States. In 2018, the amount of 
cocaine and methamphetamines seized in certain parts of 
the country exceeded that of opioids.3  
The number of people using stimulants for the first time 
has significantly increased since 2015,4 and while the trend 
in overall stimulant use is concerning, increases in related 
overdose deaths may be even greater cause for alarm. 
STIMULANT USE IN PAST YEAR ACROSS GENERAL 
POPULATION, 2007-2018
*Source: CDC WONDER; NCHS, National Vital Statistics System, 
Mortality
In 2018, 5.5 million people 
in the United States aged 12 
or older used cocaine within 
the past year and 1.9 million 
people aged 12 or older 
used methamphetamine in 
the past year.4  
Treatment of Stimulant Use Disorders
Issue Brief 5
The number of cocaine- and other psychostimulant-related 
deaths has climbed sharply over the past few years. This 
can be partially explained by an increase in polydrug use. 
In recent years, more than 50 percent of all stimulant-
related overdose deaths have also involved opioids.5 
Specifically, the practice of intentional or unintentional 
misuse of fentanyl (a synthetic opioid pain reliever) with 
stimulants is on the rise. Much of the methamphetamines 
and cocaine sold on the streets contain unpredictable 
levels of fentanyl. People buying these street products 
are often unaware of the combination of stimulant and 
fentanyl which suppresses respiration and increases the 
risk for overdose and death.  
STIMULANT-RELATED OVERDOSE DEATHS ACROSS 
GENERAL POPULATION, 2007-2018
*Source: CDC WONDER; NCHS, National Vital Statistics System, 
Mortality
Cocaine misuse is highest among adults aged 18 to 
25, while methamphetamine misuse is highest among 
those aged 26 to 49. Methamphetamine misuse rates are 
particularly high among American Indians and Alaska 
Natives (AI/AN) who, according to Centers for Disease 
Control and Prevention (CDC) data, also have the highest 
risk for methamphetamine-related overdose deaths. 
These data also show that Black or African American 
communities have the highest risk for cocaine-related 
overdose deaths.6 
PERCENTAGE OF POPULATION WITHIN SPECIFIC 
AGE GROUPS WHO REPORT USING STIMULANTS 
WITHIN THE PAST YEAR, 2018
*Source: National Survey on Drug Use and Health, 2018
** Numbers in parentheses represent total populations for the 
specific age groups. 
PERCENTAGE OF POPULATION WITHIN SPECIFIC 
RACES WHO REPORT USING STIMULANTS WITHIN 
THE PAST YEAR, 2018
*Source: National Survey on Drug Use and Health, 2018
NH/OPI: Native Hawaiian and Other Pacific Islanders
AI/AN: American Indian Alaska Native
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Research highlights some of the reasons different genders 
give for using stimulants. For example, females cite 
“increased energy,” while males cite “enhanced sexual 
experience” as their prime reasons.7  There are also 
geographical differences in the prevalence of stimulant 
misuse across the country, with cocaine used more widely 
in eastern states and methamphetamines used more in the 
West and Midwest.8
Impact of the Problem 
Short-Term Impact 
The short-term effects of stimulant use vary depending on 
several factors, including the combination of substances 
used, route of administration, potency, dosage, and level 
of prior use. However, in broad terms, stimulants are 
known to cause increased wakefulness, reduced appetite, 
and feelings of euphoria brought on by the rapid release 
of neurotransmitters, including dopamine, serotonin, and 
norepinephrine.9-10
The adverse effects of stimulant use are well-
documented. Stimulant use can cause acute conditions, 
such as accelerated heart rate, vasoconstriction, and 
bronchodilation, which stress the cardiovascular 
system.10-11 Likewise, use can produce elevated body 
temperature, which can result in potentially deadly 
hyperthermia, either alone or in combination with 
environmental factors.10 In addition, stimulant use can 
cause a host of adverse psychological or neurological 
effects, including panic attacks, hostility, paranoia, 
psychosis, and even violent behavior.12-14 and secondary 
complications such as local injection site infections, life-
threatening sepsis, and/or neurological toxicity.15  
Stimulant overdose can cause other serious symptoms, 
including hypertension, fainting, seizures, and death.16 
As is evident by overdose data, the number of stimulant 
overdoses resulting in death are climbing dramatically. 
The subacute effects of stimulant use are often 
experienced once the initial drug reaction of wakefulness 
and euphoria wear off. These effects can include fatigue, 
depression, chronic insomnia, increased appetite, impaired 
memory, and anhedonia (the inability to feel pleasure).17-19 
Long-Term Impact 
Chronic stimulant use may result in a number of health 
issues. In the long-term, persistent hypertension and a host 
of other serious cardiovascular complications can occur, 
such as angina, valvular disease, stroke, and an increased 
risk for heart attack.10, 20-21 
Chronic stimulant use can permanently alter brain 
structure, leading to impaired cognitive, neurological, and 
emotional systems. Because stimulant use releases large 
amounts of dopamine and serotonin, chronic use may 
cause mood fluctuations, anxiety, and depression, even 
when not taking the drug(s). Long-term use of cocaine 
and methamphetamines can cause decreased attention, 
confusion, impaired memory, inhibited impulse, and 
reduced motor skills.22-24 These long term impacts pose 
challenges for recovery, but successful treatment can 
enable people to return to a productive and meaningful life.
Depending on the substance used and the route 
of administration, chronic stimulant use may also 
cause a variety of other adverse physical effects. 
Methamphetamine use, for example, may result in 
“meth mouth,” a condition characterized by rapid tooth 
decay and gum disease.25 Nasal ingestion (snorting) may 
result in loss of smell, a deviated septum, frequent nose 
bleeds, and other damage to the nasal cavity.26 Smoking 
stimulants may result in lung and airway damage.27 28-2
Impact on Society  
Stimulant use also has detrimental societal effects, 
including negative outcomes for children who have a 
parent who uses, heightened crime in communities, 
costs associated with enforcement and incarceration, 
environmental damage, and premature deaths. 
Stimulant use by pregnant mothers can have long-term 
health and development consequences for their children 
(e.g., delayed motor development, poor language skills, 
and cognitive and behavioral issues). Babies born to 
mothers who use stimulants are often premature and 
smaller in size than babies born to mothers who did not.30-31
Between 2008 and 2015, amphetamine-related 
hospitalizations more than tripled, increasing 
from 55,447 instances to 206,180.28 As of 2019, 
methamphetamine has surpassed opioids as the 
leading cause of overdose death in many western 
U.S. states.29
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Continued stimulant use by one or both parents is also 
associated with neglectful or abusive parenting, as well 
as higher prevalence of children entering the foster care 
system and using stimulants themselves.32-34 
People who use methamphetamines are more likely to 
perpetrate domestic violence than those who do not. 
They are also more likely to commit property crimes than 
ASSOCIATION WITH RISKY 
BEHAVIOR 
People who use stimulants are more likely to 
engage in unprotected sex and sex with multiple 
partners.37- 38 In addition, intravenous administration 
of stimulants may result in reusing or sharing 
needles, syringes, and other paraphernalia. These 
behaviors place people who misuse stimulants 
at higher risk for HIV and other blood-borne 
pathogens, such as hepatitis B and hepatitis C. 
This is of concern because chronic stimulant use is 
linked to weakened immune response, increased 
susceptibility to infection, and accelerated retroviral 
replication.1, 30-31 
individuals who misuse other substances.35-36 Powder 
cocaine, crack cocaine, and methamphetamine-related 
offenses accounted for more than 75 percent of all 
federally-sentenced drug offenses.39 
The process used to produce and synthesize stimulants 
in clandestine laboratories can release toxins into the 
environment and create hazardous by-products. These 
conditions can cause explosions–a potential harm to those 
in the laboratory and neighboring community.40-41 The 
U.S. Department of Justice estimates that every pound of 
methamphetamines produced results in five to six pounds 
of hazardous waste, which is rarely disposed of properly.42 
The greatest societal costs of stimulant use are associated 
with adverse health effects and, tragically, premature 
deaths. Amphetamine-related hospital costs totaled 
$436 million in 2003, and increased to $2.17 billion by 
2015.28 Cocaine overdose caused 14,666 deaths in 2018; 
methamphetamines and other psychostimulants caused 
12,676 deaths. Overall, stimulant-related deaths in 2018 
accounted for roughly 40 percent of all overdose deaths in 
the United States.6   
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The purpose of this chapter is to provide an overview of 
four practices to treat stimulant use disorders: 
•	 Motivational interviewing 
•	 Contingency management 
•	 Community reinforcement approach 
•	 Cognitive behavioral therapy 
Stimulant use disorders not only have adverse effects on 
the physical and mental health of individuals, but they 
are also a public health problem with significant negative 
impacts on society. In the absence of pharmacological 
treatment that are approved by the U.S. Food and Drug 
Administration (FDA), practitioners rely heavily on 
behavioral and psychosocial interventions and practices. 
Literature around these practices is often inconsistent, 
making identification of the most effective treatment 
methods challenging.1 
Through an extensive literature review and consultation 
with experts, authors identified four practices used to treat 
stimulant use disorders. Based on a systematic review of the 
available evidence, each selected practice received a rating. 
Practice Selection 
To be considered for inclusion in this guide, eligible 
practices had to meet the following criteria: 
•	 Must be clearly defined and replicable 
•	 Address stimulant misuse reduction as a primary 
outcome 
•	 Are currently in use 
•	 Provide evidence of effectiveness 
•	 Have accessible resources for implementation 
and fidelity 
Evidence Review and Rating
Authors completed a comprehensive review of published 
research for each selected practice to determine its 
strength as an evidence-based practice. Eligible research 
studies had to:
•	 Employ a randomized or quasi-experimental 
design, or 
•	 Be a single sample pre-post design or an 
epidemiological study with a strong counterfactual 
study (i.e., a study that analyzes what would have 
happened in the absence of the intervention). 
Descriptive and implementation studies, and meta-
analyses were not included in the review, but 
were documented to provide context and identify 
implementation supports for the practices.
Each eligible study was reviewed for evidence of 
measurable reductions in stimulant use. In addition, 
trained reviewers checked each study to ensure rigorous 
methodology, asking questions such as:
•	 Are experimental and comparison groups 
demographically equivalent, with the only 
difference being that participants in the 
experimental group received the intervention and 
those in the comparison group received treatment 
as usual or with no or minimal intervention?
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•	 Was baseline equivalence established between 
the treatment and comparison groups on 
outcome measures?
•	 Were missing data addressed appropriately?
•	 Were outcome measures reliable, valid, and 
collected consistently from all participants?
Using these criteria, each study’s causal impact was 
assessed and given a rating of low, moderate, or high. 
Only randomized controlled trials, quasi-experimental 
designs, and epidemiological studies with a strong 
comparison were eligible to receive a high or moderate 
rating.
After all studies for a practice were assessed and rated, the 
practice was placed into one of three categories based on 
its causal evidence level.4
4 See Appendix 2 for more information about the evidence review 
process.
Causal Impact: Evidence demonstrating that 
an intervention causes, or is responsible for, 
the outcome measured in the study’s sample 
population.
Strong Evidence 
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Motivational Interviewing 
Goal
Motivational interviewing (MI) is a treatment approach 
that helps individuals overcome ambivalent feelings 
and insecurities. In the process, individuals become 
motivated to change their behavior and reduce or stop 
their stimulant use. 
Five underlying principles guide how providers should 
interact with clients while using this practice.2 Providers 
should:
• Express empathy through reflective listening
• Identify discrepancies between a client’s goals
or values and their current behavior
• Avoid arguments and direct confrontations with
a client
• Adjust to a client’s resistance rather than
opposing it directly
• Support self-efficacy and optimism
Typical Settings
Motivational interviewing is effective in a wide range 
of healthcare settings, from primary healthcare clinics 
to general or specialized hospitals. Studies included in 
this evidence review tested the effectiveness of MI for 
treating people with stimulant use disorders in walk-in 
health clinics, urban trauma centers, private or university-
run health clinics, community-based health clinics, and 
community-based sites.
Demographic Groups for Intervention
Motivational interviewing is intended for use across 
genders, ages, races, and ethnicities.3-4 This counseling 
approach can also be used with specific groups within the 
population, such as men who have sex with men.5 
OUTCOMES ASSOCIATED WITH 
MOTIVATIONAL INTERVIEWING
Studies included in this evidence review 
demonstrated that use of MI for people with 
stimulant use disorders was associated with 
reductions in: 
• Number of days of stimulant use
• Amount of stimulant used per day
All outcomes were measured using either urine 
toxicology or participant self-report. The time 
between treatment and follow-up varied from 
zero months (immediately post-treatment) to six 
months. 
Developers of motivational interviewing define it 
as “a directive, client-centered counselling style 
for eliciting behavior change by helping clients 
explore and resolve ambivalence.”2
Identification of Practices Associated with Treatment of 
Stimulant Use Disorders
Studies typically included adult participants who were aged 
18 and older, had no language barriers, and met criteria in 
the Diagnostic and Statistical Manual of Mental Disorders 
(DSM) for stimulant use disorders either through screening 
or self-report. Individuals with cognitive impairment, 
serious mental illness, suicide risk, or inability to provide 
informed consent were not included in these studies. 
This evidence review also included studies, each of which 
included one of the following participant characteristics: 
• Adolescents and younger adults (ages 16–22)
• Men who have sex with men
• Individuals who exhibit co-occurring psychotic
disorders (not requiring acute in-patient
psychiatric services)
• Patients with intentional or unintentional
traumatic injury
Practitioner Types
Motivational interviewing is intended for use by a wide 
variety of practitioners, including primary care and 
behavioral health professionals, peer providers, and 
criminal justice personnel. Training on MI is available for 
clinicians, non-clinicians, peers, and those with minimal 
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Studies of MI for treating stimulant use disorders 
involved clinical staff who were trained in the approach. 
These clinicians were either trained community workers 
or bilingual peers (experienced substance use outreach 
workers who were themselves in recovery). 
Intensity and Duration of Treatment 
Use of MI for reducing substance use, and, more 
specifically, for reducing and ending stimulant use, does 
not have a prescribed time period; it can range from 
a single session of 15 minutes to multiple hour-long 
sessions. This review of recent studies shows that there 
are no generalizable conclusions around the number or 
length of sessions needed to reduce stimulant use. 
web-based, facilitating access for people in geographically 
diverse and difficult to reach places.9-10 
Studies included in this evidence review tested the 
effectiveness of CM for treating people with stimulant use 
disorders at community-based substance use or mental health 
clinics, private or university-run health clinics, methadone 
maintenance facilities, and community-based sites. Two 
studies also had a web-based component of CM.11
Demographic Groups for Intervention 
Contingency management is used across genders, ages, 
races, and ethnicities in both individual and group 
settings. The approach can also be used with specific 
groups within the population, such as men who have sex 
with men, people with co-occurring opioid use disorders, 
and individuals with severe mental disorders.12-15
Studies included in this evidence review involved adult 
participants who were aged 18 and older, had no language 
barriers, and met criteria in the DSM for stimulant use 
disorders either through screening or self-report. 
OUTCOMES ASSOCIATED WITH 
CONTINGENCY MANAGEMENT
Studies included in this evidence review 
demonstrated that use of CM for people with 
stimulant use disorders was associated with 
reductions in: 
• Number of days of stimulant use
• Stimulant cravings
• New stimulant use
• HIV risk behaviors
All outcomes were measured using either urine 
toxicology, participant self-report, or the Addiction 
Severity Index Scale.11 The time between 
treatment and follow-up varied from zero months 
(immediately post-treatment) to nine months.
Contingency Management  
Goal
Contingency management (CM) is a type of behavioral 
therapy grounded in the principles of operant 
conditioning. Operant conditioning is a method of 
learning in which desired behaviors are reinforced with 
prizes, privileges, or cash. 
For treatment of stimulant use disorders, incentivized 
behaviors might include:
• Attendance at treatment sessions
• Adherence to prescribed medications for other
health conditions
• Provision of stimulant-negative urine specimens
In a clinical setting, reinforcement is often provided in the 
form of vouchers that can be exchanged for retail goods and 
services. It may also include access to certain privileges, the 
opportunity to win a prize, or even direct cash payments. 
While CM may be structured in several different ways, 
two widely used approaches include:
• The Fishbowl Method (popularized by Dr.
Nancy Petry) where clients who have earned an
incentive draw a token from a “fishbowl” for a
chance to win a prize of varying value
• Voucher-Based Reinforcement Therapy
(popularized by Dr. Stephen Higgins) where clients 
earn vouchers for completion of desired behaviors
with the level of vouchers increasing according to
an escalating schedule of reinforcement
Typical Settings
A wide range of healthcare settings, including primary 
healthcare clinics, community outpatient programs, and 
inpatient settings, can use CM effectively.6-8 In addition, 
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Practitioner Types
A variety of professionals, such as primary care 
physicians, behavioral health professionals, and criminal 
justice personnel, can implement CM.16-18 Training or 
coursework in behavioral analysis is available to support 
implementation of this intervention. 
For most studies in this evidence review, research staff, 
who may or may not have had clinical backgrounds, 
implemented the CM procedures. Some studies specified 
that these staff were trained and tested on CM protocols, 
often with the use of scripts or role-play. 
Intensity and Duration of Treatment 
Contingency management therapy does not have a 
prescribed time period, as it consists of a reinforcer-
based framework often used in combination with other 
therapies. Many clinical evaluations of CM follow a 12-
week schedule and feature frequent drug screenings (two 
to three times weekly). 
public outpatient treatment facilities, and urban treatment 
facilities that offer both inpatient and outpatient services. 
One study also used an online CRA learning program.
Demographic Groups for Intervention 
The community reinforcement approach is used across 
genders, ages, races, and ethnicities in both individual and 
group settings. The adolescent version of CRA involves 
immediate family in the treatment program. There is 
also a family training version that aims to increase the 
client’s engagement in the program through a concerned 
significant other. 
Studies included in this evidence review involved adult 
participants who were aged 18 and older, had no language 
barriers, and met criteria in the DSM for stimulant use 
disorders either through screening or self-report. 
OUTCOMES ASSOCIATED WITH 
THE COMMUNITY  
REINFORCEMENT APPROACH
Studies included in this evidence review 
demonstrated that use of CRA for people with 




• Drug use (e.g., number of weeks of
usage, frequency per week, amount spent
per week)
All outcomes were measured using either 
urine toxicology, participant self-report, or the 
Addiction Severity Index Scale. The time between 
treatment and follow-up varied from zero months 
(immediately post-treatment) to nine months.
Community Reinforcement Approach 
Goal
One behavioral therapy approach that is commonly used 
in combination with CM is the community reinforcement 
approach (CRA). This treatment was originally developed 
by Nathan Azrin and his colleagues for alcohol use 
disorder, and was later adapted for stimulant use disorder, 
particularly cocaine use. The goal of CRA is to identify 
behaviors reinforcing stimulant use and make a substance-
free lifestyle more rewarding than one that includes drugs 
and alcohol. 
CRA includes multiple elements such as such as 
analyzing clients’ substance use, relationship counseling, 
vocational guidance, and job skills training. CRA therapy 
also focuses on building social and drug refusal skills. 
Ultimately clients are encouraged to make substantial 
behavioral changes, engage in new recreational activities 
and develop new social networks.19 
When used in combination with CM, clients who 
demonstrate positive behaviors such as drug abstinence, are 
typically provided material incentives to encourage skills 
development to build a rewarding substance-free life.
Typical Settings
The community reinforcement approach is often 
delivered through inpatient programs, home visits, and 
in combination with incentives/vouchers. Practitioners 
can also implement it successfully in a typical outpatient 
treatment context, where they see clients weekly at a 
clinic.20 
Studies included in this evidence review tested the 
effectiveness of CRA for treating people with stimulant 
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Practitioner Types
A variety of professionals who possess strong, 
fundamental counseling skills, such as supportiveness, 
empathy, and a caring attitude, can implement this 
approach. This could include primary care and 
behavioral health professionals as well as pharmacists. 
CRA requires therapists to be directive, energetic, and 
engaging. 
For most studies in this evidence review, clinical staff 
implemented CRA by following procedures outlined in 
the manual A Community Reinforcement Plus Vouchers 
Approach.21
Intensity and Duration of Treatment 
Per the manual mentioned above, CRA recommends a 
24-week treatment program. Each week, clients meet one 




A newer approach to CBT uses a digital format 
for delivery to clients. This format draws on the 
National Institute on Drug Abuse’s CBT manual 
and offers CBT sessions either online or through 
an app. Computer-based CBT can be used in 
regular clinical settings as an effective supplement 
to usual outpatient treatment for stimulant 
dependence.23 
Given the multimedia format of the treatment, it is 
more affordable and can be made more broadly 
available than standard therapy treatments. 
Additionally, computer-based CBT can help reach 
and serve minority or geographically remote 
groups who may have limited access to such 
services. 
Cognitive Behavioral Therapy 
Goal
Cognitive behavioral therapy (CBT) is a short-term, goal-
oriented psychotherapy treatment that enables individuals 
to understand their current problems, challenges, and 
experiences in order to change their behaviors and 
patterns of thinking. CBT helps clients develop accurate 
assessments of circumstances and their feelings so 
they can develop realistic strategies. CBT is used also 
to address depressive cognitions and other cognitive 
distortions associated with depression, generalized anxiety 
disorders, and substance use disorders. 
Through CBT, people with stimulant use disorders are 
trained to evaluate faulty patterns of thinking, actions, 
and negative feelings associated with their drug use. CBT 
is tailored to the needs of the individual, with the goals 
Treatment of Stimulant Use Disorders
What Research Tells Us 16
of each therapy session uniquely based on the client’s 
experiences with stimulant use and personal circumstances. 
Typical Settings
Practitioners can use CBT effectively in a wide range 
of healthcare settings, from inpatient psychiatric 
rehabilitation to community outpatient programs.22 
Studies included in the current evidence review looked 
at CBT’s use in private health clinics, community-based 
outpatient treatment programs, outpatient methadone 
programs, and through online formats. 23
Demographic Groups for Intervention
Cognitive behavioral therapy is a widely used approach, 
employed across genders, ages, races, and ethnicities.24 
Studies reviewed for this guide included participants aged 
18 and older who met DSM criteria for stimulant use 
and dependence, and who did not have any other mental 
illness or psychotic disorder needing more intensive or 
targeted treatment and only one study focused on men 
who have sex with men.
OUTCOMES ASSOCIATED WITH 
TRADITIONAL AND COMPUTER-
BASED COGNITIVE BEHAVIORAL 
THERAPY
Studies included in this review demonstrated 
that CBT or computer-based CBT for people with 
stimulant use disorders were associated with 
reductions in: 
•	 Quantity of stimulants consumed per week
•	 Frequency of stimulant use per week
•	 Risky sexual behaviors
All outcomes were measured using either urine 
toxicology, participant self-report, or the Addiction 
Severity Index Scale. The time between treatment 
and follow-up varied between zero months 
(immediately post-treatment) to 12 months.
Practitioner Types
A variety of professionals trained in CBT principles can 
implement it, such as behavioral health professionals, 
primary care staff, and criminal justice personnel. The 
National Association of Cognitive-Behavioral Therapists 
offers CBT training for mental health professionals, as 
well as non-professionals with a four-year college degree. 
In the studies included in the current evidence review, 
trained clinicians delivered all in-person CBT sessions.
Intensity and Duration of Treatment 
Cognitive behavioral therapy is typically customized to 
the needs of each individual. Most people who seek CBT 
for stimulant use disorders receive counseling for a period 
ranging from 5 to 10 months. 
A standard therapeutic session is approximately 50 
minutes. During this time, the therapist and client work 
together to understand existing thought patterns associated 
with the client’s current problems and develop strategies 
to overcome those concerns. Group counseling rarely 
utilizes CBT.
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Review rating Strong Evidence Strong Evidence Strong Evidence Strong Evidence
Focus of the practice Resolving clients’ 
ambivalent feelings 
and insecurities 
and enhancing the 
internal motivation 






that reinforce stimulant 
use and making a 
substance-free lifestyle 
more rewarding than one 
that includes substances
Helping clients improve 
the quality of their lives 
not by changing their 
circumstances, but 
altering their perceptions 
of those circumstances
Can be used in 
outpatient healthcare 
settings 
   
Can be used in 
inpatient healthcare 
settings
   
Specific training 
available  --  
Web-based version 
available --   
Can be practiced by 
peers  -- -- --
Has been used 
successfully with 
males and females
   
Special populations 




Men who have sex 
with men
Men who have 















intensity and duration; 
recommended for 24 
weeks
No prescribed intensity 
and duration; typical 
range of 5 to 10 months
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CHAPTER




This chapter provides information for clinicians, program 
administrators, and other stakeholders interested in 
implementing a therapy practice to treat stimulant use 
disorders. It documents some clinical issues and concerns 
health professionals may encounter when engaging and 
treating people with a stimulant use disorder, as well as 
some strategies to address those concerns. When clients 
using stimulants initiate treatment, they may present 
multiple medical and clinical symptoms. Practitioners 
should be aware of these issues, consider them thoroughly 
for each individual client, and address them effectively 
before beginning any therapy. For therapy to be 
successful, these clinical issues must be addressed not 
only at the beginning of treatment, but throughout the 
therapeutic engagement.  
Following a review of the clinical considerations for 
treating people with a stimulant use disorder, the chapter 
provides information about specific implementation 
challenges that stakeholders may encounter when 
implementing a new therapy practice. The chapter 
includes various strategies to overcome these challenges, 
along with examples from the practices reviewed in 
Chapter 2.
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CLINICAL ISSUE MANAGEMENT STRATEGY
Polydrug use An individual may use multiple substances 
to enhance the physical or psychological 
effects of each drug, to counteract the 
effects of one or more drugs, to prolong 
a drug’s effects, or to experience a new 
effect.
•	 Consider the pharmacological, psychosocial, 
and behavioral reasons for combining certain 
substances, evaluate for the presence of 
other substance use disorders, and implement 
targeted treatment options addressing all 
substances for people who use multiple drugs. 
Overdose risk Individuals who intentionally or 
unknowingly mix stimulants with fentanyl 
have an increased risk for overdose.
•	 Assess client awareness of dangers from 
fentanyl and educate about risks.
•	 Train program staff, clients, and family members 
on naloxone use and make naloxone available 
to clients, their families, and the community.
•	 Monitor clients closely for opioid overdose 
symptoms from fentanyl (or heroin) mixed with 
methamphetamine or cocaine.
Intoxication Stimulants increase euphoria, 
hyperexcitability, hypersexuality, 
locomotor activity, agitation, and psychotic 
symptoms, including paranoia and 
hallucinations.
•	 “Talk down” the client in a calm environment.
•	 For clients who exhibit severe symptoms 
of intoxication, consider pharmacological 
treatment, for example benzodiazepines, for 
acute management of agitation and distress, 
antipsychotic medication for psychosis/paranoia/
hallucinations.
Co-occurring mental 
and stimulant use 
disorders 
One of the challenges practitioners face is 
making a distinction between independent 
psychiatric disorders, psychiatric disorders 
as a result of the stimulant use, and 
psychiatric symptoms that arise from 
intoxication and withdrawal.
•	 Consider integrated treatment options 
regardless of the underlying cause for the dual 
diagnosis. 
•	 Since lack of adequate treatment for either 
disorder may interfere with an individual’s overall 
recovery, coordinate services between stimulant 
use disorder therapists and mental health 
providers if stimulant disorder treatment staff do 
not treat mental disorders.
Psychosis Stimulant use can result in psychotic 
symptoms, such as auditory and visual 
hallucinations and paranoia. Stimulant-
induced psychosis is generally transient; 
however, methamphetamine can produce 
persistent psychosis like schizophrenia. 
•	 Consider either benzodiazepine or an 
antipsychotic medication to address acute 
symptoms.
•	 Consider continuation of antipsychotic 
medications for long-term management of 
persistent psychosis.
Clinical Issues to Consider When Treating Stimulant 
Use Disorders
There are a number of issues that can present practitioners with clinical challenges and should be considered before making 
decisions regarding treatment planning. The table below summarizes the most common clinical issues encountered and 
strategies to manage them.
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CLINICAL ISSUE MANAGEMENT STRATEGY
Violence Methamphetamine use increases chance 
of violent behavior.1
•	 Be aware of the relationship between stimulant 
use and violence and be cognizant of the 
consequences of violence on individuals using 
stimulants, their families, program staff, and 
other program participants. 
Cognitive deficits Stimulant misuse leads to attention and 
memory problems that can interfere with 
functioning and treatment approaches that 
involve learning.
•	 Inform clients about cognitive deficits and use 
strategies that provide repetition of information 
and do not depend on optimal memory.
•	 Reserve treatments that require more complex 
cognitive functioning until a client’s cognition is 
restored after a period of abstinence.
Stimulant withdrawal As an individual stops stimulant use, 
he or she may experience symptoms 
like severe fatigue, insomnia, cognitive 
impairment, feelings of depression, 
anxiety, loss of energy, confusion, the 
inability to feel pleasure, and paranoia.2 
•	 Encourage rest, mild/moderate exercise, and a 
healthy diet to manage withdrawal.
Individuals may experience cravings 
associated with specific cues, such as 
objects (e.g., cash), people (e.g., drug 
user friends), other substances (e.g., 
alcohol), places (e.g., areas where 
stimulants are sold or used), time 
periods (e.g., weekends, after work), 
and emotional states (e.g., depression, 
boredom).3
•	 Educate clients in treatment about the powerful 
impact of cue-induced cravings and help them 
identify strategies to avoid situations in which 
there are “triggers.”
Withdrawal may result in hypersexuality 
and impaired sexual functioning, leading 
to psychological distress.4
•	 Educate clients about the possibility of changes 
in sexual function during early recovery.
Severity of disorder 
and level of care
Clients may receive treatment services 
at various levels within the continuum 
of care; levels ranging from prevention 
and early intervention to inpatient and 
residential services. Assessing the 
required level of care for each client 
based on the severity of client’s disorder 
is critical.
•	 Evaluate the clients’ needs and ensure that that 
they receive services at the appropriate level 
and then step up to more intense treatment or 
down to less intense treatment as needed.
Engaging and treating people actively using stimulants, in withdrawal, or in early recovery is challenging. Understanding the 
experience of the clients in conjunction with clinical concerns is essential for planning and implementing therapy practices to 
meet client needs. 
Treatment of Stimulant Use Disorders
Guidance for Selecting and Implementing Evidence-based Practices 23
Implementation 
Challenges and Strategies
In addition to the important clinical concerns for this 
population, practitioners, administrators, and community 
leaders will be most successful if they understand specific 
challenges and strategies for successful implementation 
of new practices. The following section provides details 
on specific challenges programs could face as they 
implement therapy practices, strategies to deal with those 
challenges, and the role of implementation science in 
enhancing practice implementation. 
When implementing interventions to address stimulant 
use disorders, there are several potential barriers to 
consider. Issues related to implementing motivational 
interviewing (MI), contingency management (CM), 
community reinforcement approach (CRA), and cognitive 
behavioral therapy (CBT) include:
1. Practice selection 
2. Funding, financing, and program cost
3. Program staffing
4. Coordination of care
5. Cultural adaptation of the practice
These challenges are described in detail below, along with 
potential actions to mitigate them.
Practice Selection
Challenge: 
Choosing the right intervention based on the severity of 
client’s illness and where they are in the addiction cycle. 
Strategies:
•	 The effectiveness of various treatment 
interventions may be influenced by the clients’ 
stage in the addiction cycle. It is necessary 
to consider the issue of psychosis and brain 
functioning related to active and recent stimulant 
use when choosing an intervention for stimulant 
use disorders. 
•	 MI can help clients decide to enter treatment and 
serve as a starting point in the recovery process.5 
While often implemented successfully at the 
early stages of treatment, due to its flexibility 
as an add-on component to other interventions, 
practitioners can apply motivational strategies 
throughout the recovery process.6
ROLE OF IMPLEMENTATION 
SCIENCE IN HELPING PROGRAMS 
ADDRESS IMPLEMENTATION 
BARRIERS 
Implementation science is the study of methods 
to promote the uptake of proven clinical practices, 
programs, organizational interventions, and 
policies, with the goal of improving health. Use of 
the Consolidated Framework for Implementation 
Research (CFIR) is one way programs can 
conceptualize constructs associated with successful 
program implementation. Programs can use CFIR 
as they plan and execute new programs.
The five main domains of CFIR are: 
Intervention Characteristics - Includes the 
components and attributes of the intervention, such 
as cost, strength of evidence, and complexity
Outer Setting - Consists of the external factors that 
may affect implementation, including the policy and 
regulations in effect, patients’ needs and resources, 
and the sources of implementation pressure
Inner Setting - Considers the characteristics of 
the facility contemplating implementation of a new 
program, including the organizational culture, 
available resources for implementation, and the 
facility’s overall structure
Characteristics of Individuals - Includes the 
attributes of individuals making up the organization 
contemplating program implementation, and 
includes aspects like staff attitudes towards the 
proposed intervention, self-efficacy to adopt new 
programs, and perception of the facility itself
Process - Consists of the stages and constructs 
related to implementation, namely planning, 
engaging, executing, reflecting, and evaluating 
(constructs explain how a course of action for 
implementation is charted and carried out)
Programs can use CFIR to identify both barriers and 
factors conducive to implementation. This allows 
programs to design a detailed strategies when 
considering new therapy practices.6 
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•	 CM can serve as a source of positive 
reinforcement for clients in the beginning stages 
of recovery.7 It can be combined with other 
therapies, such as CRA and vouchers, to enhance 
duration of recovery.8 
•	 CBT can be successfully applied at any stage 
of the addiction cycle or encompass the full 
cycle. CBT consists of various modules and 
add-ons (e.g., homework) that practitioners can 
specifically tailor to the client. 
Funding, Financing, and Program Cost
Challenge: 
Obtaining funding to implement treatment practices for 
stimulant use disorders is a common challenge.  
•	 Practices to treat stimulant use disorders have 
several associated costs, including:
o Planning implementation 
o Training practitioners or interventionists 
o Performing related tasks like urinalysis 
screens 
o Providing incentives or other behavioral 
reinforcement 
o Making any necessary technological en-
hancements
•	 Many state Medicaid, Medicare, and private 
insurance entities may not reimburse CM 
and computer-based CBT treatments. 
Reimbursement for both these therapies requires 
careful coordination with funding agencies.
Strategies:
•	 CM costs can be reduced by limiting access to 
only those who test positive for stimulants at 
admission, or by discontinuing the approach 
when practitioners observe no client response to 
treatment.9 
•	 Computer-based CBT has potential to substantially 
reduce healthcare costs.10-11 Automated versions 
of CM have also proven effective and can reduce 
costs of tracking participants’ urine and prize 
draw outcomes.12 As internet and computer access 
increase, these treatment options will be more 
accessible, particularly for clients in rural and 
remote locations.9 
•	 Additional funding sources, such as federal, 
state, and private grants, as well as contributions 
from or opportunities to share costs with 
community partners can help overcome barriers 
to funding CM reinforcers. 
•	 SAMHSA suggests soliciting in-kind donations 
(which might prove particularly effective at 
providing CM incentives) and make use of 
volunteers or internships to cut costs.13
Program Staffing
Challenges: 
•	 It is vital that properly trained staff be available 
to successfully implement a new treatment 
program or practice and to build program 
capacity. However, this may be difficult to 
achieve due to staff turnover and limited time for 
staff to become familiar with the program.
•	 Practitioners without clinical backgrounds can 
deliver MI and CM. In contrast, CBT is often 
delivered by clinically trained professionals. 
Further, CBT is complex to administer, making 
it difficult to adapt and tailor to a particular 
setting.9
•	 Ongoing supervision and reflective practice 
are essential elements for most stimulant use 
disorder interventions to ensure fidelity of 
implementation.14-15
According to the Surgeon General’s Report on 
Alcohol, Drugs, and Health, the three stages of 
addiction are:
1. Binge and Intoxication - The stage 
at which an individual consumes an 
intoxicating substance and experiences its 
rewarding or pleasurable effects
2. Withdrawal and Negative Affect - The 
stage at which an individual experiences a 
negative emotional state in the absence of 
the substance
3. Preoccupation and Anticipation - 
The stage at which an individual seeks 
substances again after a period of 
abstinence
Some interventions are better suited at the 
starting point of recovery within the early stages of 
stimulant misuse, whereas others can be tailored 
for the end of the addiction cycle, specifically for 
relapse prevention and treatment.
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Strategies:
•	 Computer-based CBT can be a viable substitute 
for in-person CBT, as it requires minimal staff 
assistance and has a degree of flexibility in 
implementation. 
•	 Self-study and the “train-the-trainer” method 
can help practitioners learn how to conduct MI, 
though with varying degrees of effectiveness.16 
While self-study does not require an instructor, 
a train-the-trainer approach entails sending staff 
to an expert-led workshop. After learning the 
practice from an expert, these staff typically 
complete a certification process to become 
trainers themselves and then train other staff. 
•	 Having a facilitator—whether an external or 
internal supervisor—can be a key factor in 
successfully implementing practices for stimulant 
use disorders. For example, practitioners using MI 
typically need three or four coaching sessions.14
Coordination of Care
Challenge:
•	 Individuals with stimulant use disorders may 
have other health care needs such as  HIV17 or 
life situations affecting their health and recovery 
(e.g., experiencing homelessness).18 Substance 
use disorders and recovery from them are often 
associated with social determinants of health 
such as income and housing instability. 
Strategies:
•	 Using a whole-person approach, practitioners 
need to coordinate treatment for stimulant use 
disorders with care for clients’ other health 
needs. 
•	 Models focused on care coordination, including 
physical, mental, behavioral, and stimulant-
use-specific services are more successful than 
those attempting to treat only the  stimulant use 
disorder.19 
•	 Whenever possible, co-location of stimulant 
use disorder treatment with primary care and 
other services allows for improved coordination 
between physical and mental health care.20 
•	 Other life circumstances, such as low income, 
experiencing homelessness, domestic violence, 
and child maltreatment, also affect the 
success of stimulant use disorder treatment. 
Coordination of care should encompass these 
social determinants of health and providers 
should attempt to integrate resources and social 
supports from the client’s community.
•	 Stimulant use treatment providers are well 
positioned to support systemic changes to 
address social determinants in their community. 
Providers and other stakeholders can identify 
gaps in services and promote additional 
resources to improve social and economic 
conditions of their clients.
Cultural Adaptation of Practices
Challenge: 
•	 Behavior change interventions are most effective 
when they are responsive to the clients’ cultural 
practices and ideologies.21-22
•	 When behavior change interventions are adapted 
to make them responsive to clients’ needs, program 
staff may find it challenging to adhere to the 
fidelity of the practice. They may find it difficult 
to maintain the core elements and foundational 
principles of the practice during implementation.
Strategies: 
•	 Motivational techniques are adaptable for 
different cultures. The processes of change and 
motivational enhancement can be tailored to the 
values, beliefs, and experiences of individuals 
within different ethnic and racial categories. 
•	 To ensure adapted practices are implemented 
with their core elements upheld, it is incumbent 
on those doing the adaptation to collect rigorous 
data to assess the intervention for fidelity to the 
practice.
•	 When programs are not able to maintain fidelity 
to the established practice, a rigorous evaluation 
of the adapted practice provides evidence of the 
impact of the adapted practice on stimulant use.
Cultural adaptation of interventions has been 
defined as “the systematic modification of an 
evidence-based treatment (EBT) or intervention 
protocol to consider language, culture, and 
context in such a way that it is compatible with the 
client’s cultural patterns, meanings, and values.”21 
Culturally adapted health interventions are more 
effective than usual care.22 
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•	 For American Indian/Alaska Native 
communities, the focus of motivational 
interviewing on an equal or balanced 
relationship between the therapist and the 
client seems to fit well with cultural norms.23 
Motivational interviewing can also be readily 
incorporated into tribal practices like Talking 
Circles and Sweat Lodge Ceremonies.24
Practice Resources
In addition to the introductory, overarching 
implementation guidance provided above, there are 
several manuals and resources developed specifically to 
help stakeholders implement the practices described in 
Chapter 2. Please note that this guide is not intended to be 
a training manual, but additional resources are available to 
support implementation of these practices
Motivational Interviewing Resources
Motivational Interviewing Network of Trainers (MINT) is 
an international organization affiliated with the developers 
of MI, Bill Miller and Steve Rollnick. The website has 
resources for MI trainings and upcoming events.
TIP 35: Enhancing Motivation for Change in Substance 
Use Disorder Treatment is a SAMHSA publication 
outlining motivational strategies and how to use them in 
treating substance use disorders.
Motivational Interviewing Supervision and Training Scale 
(MISTS), Motivation Interviewing Skill Code (MISC), 
Assessment of Motivational Interviewing Groups—
Observer Scale (AMIGOS) and Motivational Interviewing 
Treatment Integrity (MITI) are all measures for evaluating 
various aspects of MI practice.
Contingency Management Resources
Motivational Incentives-A Proven Approach to Treatment 
provides information and resources on the implementation 
of CM practices. This includes an initial training, an 
interactive online course, and free software for managing 
CM clients.
A Treatment Manual for Implementing Contingency 
Management provides a CM treatment manual that gives 
attention to prisoner and parolee populations.
Contingency Management: Using Motivational 
Incentives to Improve Drug Abuse Treatment  provides 
an overview of CM principles, a case study of a program 
using CM, and guidance regarding how to implement 
and supervise CM procedures. 
The Contingency Management Competence Scale is 
available for both treatments reinforcing abstinence and 
attendance. The scale is intended to be used as a fidelity 
tool, and the associated manual provides suggestions for 
optimal implementation of CM. 
Contingency Management Incentives for Sobriety 
provides an overview of CM, its early research, and 
the research supporting its use in treating alcohol use 
disorders and polydrug use. 
Developing a Measure of Therapist Adherence to 
Contingency Management: An Application of the Many-
Facet Rasch Model describes the development of an 
adherence tool for CM. 
Identifying Provider Beliefs Related to Contingency 
Management Adoption Using the Contingency 
Management Beliefs Questionnaire describes the 
development of a 32-item questionnaire used to assess 
providers’ beliefs regarding CM treatment interventions. 
Community Reinforcement Approach (CRA) 
Resources
A Community Reinforcement Plus Vouchers Approach: 
Treating Cocaine Addiction describes how to implement 
a CRA that adds a voucher component, primarily with 
cocaine-using populations. The manual describes the 
clinical treatment approach, as well as tips related to co-
occurring psychiatric disorders and treatment supervision. 
The Community Reinforcement Approach provides an 
overview of CRA and the research supporting its efficacy.
Chestnut Health Systems EBTx Center offers training and 
certification for CRA and Adolescent CRA.
Robert J. Meyers Website from one of the developers of 
CRA, includes background information for the practice, 
details of ongoing trainings, and links to relevant 
publications. 
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Community Reinforcement and Family Training, Support 
and Prevention (CRAFT-SP) provides a treatment manual 
for CRAFT, an outgrowth of CRA. The manual outlines 
seven treatment sessions and describes the theoretical 
framework for the intervention.
Cognitive Behavioral Therapy (CBT) Resources
Academy of Cognitive Therapy is a group of mental 
health professionals practicing CBT. The website provides 
multiple resources for both administrators and clients, 
training, and certification for CBT administrators. It also 
offers assistance with program implementation.
Beck Academy offers training and certification for CBT 
administrators (i.e., professionals, educators, graduate 
students). The website includes online training courses, 
in-person workshops, newsletters, and other resources. It 
also offers assistance with program implementation and 
utilizing supervisors and consultants. 
SAMHSA Website provides CBT guidelines, training 
manuals, toolkits, workbooks, and training modules. 
It also includes resources for implementing CBT with 
specific populations and for specific applications (e.g., 
substance use disorders, anger management, mental health 
issues). Resources are also available in multiple languages 
like Spanish and Chinese. 
CBT4CBT is a self-guided, web-based program with 
various online modules. The program can be accessed 
through provider or client log-in (paid access). The 
website also has an additional CBT toolkit available for 
purchase. 
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4
CHAPTER
Examples of Stimulant 
Use Treatment 
Programs
This chapter highlights three community examples of 
program models providing treatment services and support 
to people with a stimulant use disorder and documents how 
each uses one or more of the practices with strong evidence 
detailed in Chapter 2: 
•	 Motivational Interviewing 
•	 Contingency Management 
•	 Community Reinforcement Approach 
•	 Cognitive Behavioral Therapy  
The chapter describes how each program has implemented 
these practices as part of a comprehensive strategy to 
address the needs of their populations. 
Programs should implement practices with fidelity to 
evaluated models. Fidelity is the degree to which a 
program delivers a practice as intended and must be 
maintained for desired therapy outcomes. However, many 
programs adapt chosen practices to better serve their 
clients. As practitioners modify these practices to address 
the needs and constraints of their population, budget, 
setting, and other local factors, they should adhere to the 
practice’s foundational principles. 
The three programs in this chapter were identified 
through an environmental scan and in consultation with 
experts. At this time, each of the programs predominantly 
serves a distinct population, namely people experiencing 
homelessness, members of a federally recognized tribe, 
and gay and bisexual men who have sex with men (MSM). 
Although the programs highlighted below are population 
specific, the practices they implement have strong 
evidence, target a range of stimulants, and can successfully 
serve a wide range of geographically, racially, and 
ethnically diverse populations. These programs are meant 
to be implementation examples and have not been subject 
to rigorous evaluation.
To be included in this chapter, programs had to: 
•	 Implement one or more of the practices 
identified in Chapter 2
•	 Be replicable (well-defined with guidance 
materials or a manual)
•	 Have research to support their impact on 
stimulant use 
•	 Provide appropriate and effective interventions 
for varied stimulant types, geographic areas, 
practice settings, and diverse populations
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The HPHP primary care facility provides CM as an 
optional component of the Medication-Assisted Treatment 
(MAT) Program. The CM program was initially introduced 
as a 12-week pilot to address the needs of polydrug 
users and former opiate users who were struggling with 
methamphetamine. MAT patients who have positive urine 
drug screens, with exception of buprenorphine and THC, 
are eligible for the program and can opt-in by signing a 
patient agreement form during intake. 
The program employs the “fishbowl” method of CM. 
Participants with negative weekly or biweekly urine samples 
are eligible for one to three weekly drawings. Drawings 
offer $5 to $50 gift cards, or positive affirmations, and occur 
during the program’s group psychotherapy sessions provided 
as a part of the MAT program.  
The program was initially launched in early 2019 at a 
clinic run by the Health Services Agency of the County 
of Santa Cruz and is led by the MAT clinic nurse. The 
program has since expanded to the Agency’s two other 
clinics. It began with 20 to 25 participants and a total 
project budget of about $750 for a 12-week session. 
Model Features and Elements
•	 CM Patient Agreement to facilitate voluntary 
enrollment and ensure patient understanding of 
the program.
•	 Active outreach by program staff in their 
community to build rapport with people 
experiencing homelessness and make their 
transition into the program easier. 
•	 Weekly or biweekly urine drug screens. 
•	 Weekly “fishbowl” drawings for $5 to $50 gift 
cards and positive affirmations for clients with 
negative urine drug screens.
•	 Weekly group psychoeducation sessions 
using a variety of manualized programs, such as 
“Seeking Safety,” an evidence-based, present-
focused counseling model to help people attain 
safety from trauma and substance use.
•	 Twelve-week cycles with the option to continue 
to a new cycle depending on stage of recovery.
Practice implemented by program
Contingency Management
Setting
Outpatient; Organization is a full-service, primary 
care center serving the needs of homeless and 
low-income populations in Santa Cruz County.
Population of Focus
People experiencing homelessness receiving 
MAT for stimulant use. Typical clients are males, 
Caucasians, with ages ranging from 20 to 60 years.
Program Duration
One session is considered 12 weeks. 
Related Resources




Homeless Person Health Project (HPHP)
County Health Services Agency (Santa Cruz County, CA)  
www.santacruzhealth.org
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Findings and Outcomes
•	 Data before and after treatment indicated an 
increase in negative urine drug screens, from 41.6 
percent at baseline to 72 percent at week 48.
•	 Less frequent use documented through client 
self-report.
•	 Increased client attendance.
•	 Patient empowerment evidenced by optimistic 
attitudes about sobriety (e.g., client reactions 
such as “I’ll get it next time” at not receiving a 
gift card).
•	 Positive patient engagement with the program 
(e.g., excitement about sessions, clapping to 
support peers when drawing from the lottery).
Lessons Learned 
•	 Use grants to obtain resources needed to 
implement the program. Nonprofit clinics and 
programs can also ask for donations.
•	 Start small. Implementation of CM can vary 
with every program. Adaptation of CM runs 
the risk of diminishing the efficacy of the 
intervention. When possible adhere as closely 
as possible to established guidelines. When 
implemented in an integrated primary care 
setting, consider including stimulant data in 
electronic medical records of the client.
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The Rosebud Sioux Tribe Alcohol and Drug Treatment 
Program’s Methamphetamine Rehabilitation Program 
(MRP) is based on the Seven Direction Model developed 
by Ed Parsells, in consultation with cultural and spiritual 
leaders, and uses the underlying principles of MI. 
Program staff are trained in and use MI principles during 
therapeutic sessions with clients. Staff adopt a non-directive 
style of interaction, allow the client to challenge them, 
ask questions that engage clients, and encourage clients to 
examine and assess their own behaviors. Staff practice the 
MI technique of empathy while working with clients. 
The Lakota Seven Direction Model is based on the belief 
that spirituality is the foundation for recovery. It relies 
heavily on the concept of conscience and the role it plays 
in stimulant misuse treatment. The program runs for seven 
weeks, with each week focusing on a specific aspect 
of addiction, a particular Lakota value, and a positive 
behavior. For example, during the third week, the program 
focuses on the physical aspect of the addiction and 
encourages the Lakota value of courage and bravery. The 
behavior emphasized during this week is “facing fears.” 
The program is often credited for taking the abstract 
concepts of spirituality and conscience and applying them 
in the Seven Direction Model. MRP empowers people to 
engage in the process of recovery from addiction. Staff 
promote physical, mental, spiritual, and emotional wellness.
Model Features and Elements
•	 Two seven-week cycles focus on different 
curriculum. The first cycle is more didactic 
and helps clients work through their cognitive 
impairment brought on by stimulant use. The 
second cycle adds a Rational Emotive Therapy 
beyond the didactic strategy.1
Practice implemented by program
The Spirit of Motivational Interviewing
Setting
In-patient services on the Rosebud Sioux Tribe 
Reservation in South Dakota. Staff include 
counselors, treatment technicians, case 
managers, and psychologists, all of whom are 
enrolled tribal members. 
Population of Focus
Members of any federally recognized tribe.
Program Duration 
Seven weeks of Lakota Seven Direction Model. 
The program recommends two seven-week cycles. 
Related Resources




Manual for Counselors in Native American 
Communities: https://www.integration.samhsa.gov/ 
clinical-practice/ Native_American_MI_Manual.pdf 
Rosebud Sioux Tribe Alcohol and Drug Treatment 
Program, Methamphetamine Rehabilitation Program
Rational emotive behavior therapy is an active-
directive, philosophically and empirically-based 
psychotherapy with the aim of resolving emotional 
and behavioral problems and disturbances and 
helping people lead happier and more fulfilling lives.1
Goals for the first cycle: 
Goal I: Learn the Seven Directions, Seven Life Powers, 
and Seven Lakota Values
Goal II: Develop healthy communication and values and 
resolve internal conflict
Goals for the second cycle: 
Goal I: Reinforce positive changes and healthy 
communication skills
Goal II: Prevent relapse and increase efficacy 
•	 “Talking circle” (a practice for expression of 
thoughts and feelings in the context of complete 
acceptance by participants) and sweat lodge 
ceremonies practiced weekly. 
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•	 Daily, half-hour morning sessions where 
clients share their thoughts and insights. Staff 
use client sharing to determine progress.
•	 Partnership with cultural, spiritual, and 
religious leaders within and outside the 
community, who are invited to address clients 
during their recovery process. 
•	 Weekly, 45- to 60-minute equine therapy 
sessions that emphasize Lakota culture and 
values. Patterns of self-defeating thoughts, 
beliefs, and behaviors identified during the 
equine therapy activities are processed in group 
therapy immediately following the activity.
Findings and Outcomes
Sixty-six percent of clients from Quarter 1 in 2016 
completed the program, while spending an average of 145 
days in therapy. Qualitative data collected from the clients 
highlighted the positive outcomes of the program. In the 
actual words of two clients:
“The Rosebud Sioux Tribe Meth Rehabilitation Program 
not only taught me about my addiction and why I 
could not stop using meth, it also taught me how to 
live a spiritually, mentally, emotionally and physically 
fulfilling life. I no longer need to look outside myself for 
validation.”
“… MRP gave me the opportunity to take a good hard 
look at reality. In treatment I was able to find my true 
self. I was able to see all the wrongs I did to others and 
myself. Finding spirituality helped change my life. The 
RST MRP equipped me with the tools to stay sober and in 
recovery… I will continue to work my recovery program 
using the tools and skills taught at the RST MRP.”
Lessons Learned 
Court-mandated clients complete the entire program. 
Self-referred clients typically terminate the program 
prematurely after about two to three weeks. They may 
need extra encouragement around that time to continue 
the program. Once the self-referred clients stay in the 
program through the first cycle of seven weeks, they tend 
to continue and complete the program. 
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Practice implemented by program
Motivational Interviewing and Cognitive 
Behavioral Therapy for relapse prevention
Setting
Outpatient; Sessions occur at Mount Sinai West 
Hospital in New York City.
Population of Focus
Gay and bisexual men who have sex with men.
Program Duration
There is no prescribed length for the program. 
Typically, clients stay in the program for anywhere 
from a few months to over a year. Length is 





Dialectical Behavior Therapy: 
https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2963469/
The Crystal Clear Project (Methamphetamine) is designed 
to address the needs of gay and bisexual men who have 
sex with men (MSM) who misuse methamphetamines. 
The program provides an accepting and culturally sensitive 
environment where clients are encouraged to engage in 
open conversation about alcohol and drug use, sexual 
behaviors and intimacy, and how experiences related to 
homophobia and sexual orientation may have contributed 
to their drug use. The program’s goals are to reduce 
methamphetamine use and risky sexual behavior.
All program staff are trained in motivational interviewing 
and adhere to its principles in their daily interactions with 
clients. Staff also employ Dialectical Behavior Therapy 
and “Getting Off,” an adaptation of Cognitive Behavioral 
Therapy (CBT) focused on the needs of MSM.  
Each client’s treatment is tailored to his individual needs 
and considers the severity of his use and the amount of 
structure he needs and is willing to accept. The program 
offers both day and evening sessions and clients can attend 
as few as one session or as many as five sessions per week. 
Model Features/Elements
•	 Team of practitioners include a family 
therapist, addiction pharmacologist, social 
worker, and psychiatrist.
•	 Holistic and culturally sensitive approach 
addresses stressors related to sexual orientation. 
•	 Individual evaluations conducted according to 
state regulations and by a psychiatrist. 
•	 One to five weekly sessions offered. Sessions 
are individual or in a group, driven by the needs 
and capacities of each client. 
•	 Self-help sessions, based on principles of Alcoholics 
Anonymous, are available but not required.
•	 Both unstructured (open process) and 
structured (following a manualized therapy) 
sessions are offered.
Findings and Outcomes
The program has not had funding to conduct an official 
program evaluation. Outcomes reported by program staff 
include:
•	 Reduction in severity of methamphetamine use 
(including lower use, as well as abstinence). 
•	 Reduction in risky sexual behaviors.
Lessons Learned 
•	 The program is exploring the potential of hiring 
peer counselors on staff. 
•	 The program requires staff that are LGBTQ 
friendly and open to discussing these issues.
•	 Conducting trainings and providing ongoing 
supervision can be helpful to raise comfort level 
of the staff, thereby increasing program success.
•	 The program directly addresses clients’ sexual 
behaviors. Crystal methamphetamine is often 
tied to sexual behaviors, so it is important to 
address these behaviors during therapy. 
Crystal Clear Project (Methamphetamine)
Mount Sinai West Hospital (New York, NY)  
https://www.mountsinai.org/locations/addiction-institute/services/outpatient
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Evaluation and Quality 
Improvement
Evaluating a practice or program answers critical 
questions. Evaluation can provide information about how 
well a practice has been implemented, and what is and is 
not working in a program. Evaluation can also show how 
a program or practice benefits clients. This can be helpful 
in securing funding by providing evidence of program 
effectiveness. In addition, stakeholders can use information 
gathered via evaluation to encourage implementation of 
that practice in other programs or communities.
This chapter provides an overview of approaches to 
evaluate implementation and results of practices to 
treat stimulant use disorders. The chapter also includes 
information on implementing a continuous quality 
improvement (CQI) process. U.S. Department of 
Health and Human Services (HHS) defines CQI as, 
“the systematic process of identifying, describing, and 
analyzing strengths and problems and then testing, 
implementing, learning from, and revising solutions.” 
CQI is an essential process for successfully implementing 
a practice. Finally, the chapter concludes with specific 
evaluation resources, including potential outcomes to track. 
Type of Evaluations and 
Study Designs
Although often overlooked, evaluation is an integral part 
of the implementation process and should be planned 
from the start. Programs should consider assessing the 
extent to which a practice can be evaluated in a reliable 
and credible fashion.
Evaluation data provide information on what did and 
did not work. For example, initial information collected 
from clients provides baseline data that can be compared 
with data collected at the end of a program. This allows 
program managers, clinicians, and other providers to assess 
changes or improvements in client attitudes and behaviors. 
Salabarría-Peña, Y., Apt, B.S., Walsh, C.M. (2007). Practical use of program 
evaluation among sexually transmitted disease (STD) programs. Centers for 
Disease Control and Prevention. https://www.cdc.gov/std/program/pupestd/
types%20of%20evaluation.pdf 
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Evaluation is typically conducted before a practice is 
implemented to determine its feasibility (formative 
evaluation), during implementation (process evaluation), 
and after the intervention has been delivered to at least 
one client (outcome and impact evaluations). All four 
types of evaluations are necessary to be able to make 
judgments about an intervention’s effectiveness on 
reducing stimulant misuse.
CONTINUOUS QUALITY IMPROVEMENT (CQI)
What is CQI?
CQI involves a systematic process of assessing program or practice implementation and short-term outcomes 
and then involving program staff in identifying and implementing improvements in service delivery and 
organizational systems to achieve better treatment outcomes. CQI helps assess fidelity, the degree to which a 
program delivers a practice as intended. 
CQI differs from process evaluation in that it involves quick assessments of program performance, timely 
identification of problems and potential solutions, and implementation of small improvements to enhance 
treatment quality. CQI is usually conducted by internal staff. Process evaluation involves longer-term 
assessments and is best conducted by an external evaluator. 
The Network for Improvement of Addiction Treatment (NIATx), a project originally funded by SAMHSA’s 
Center for Substance Abuse Treatment (CSAT), offers tools to conduct CQI and improve services in substance 
use disorder treatment settings. NIATx is based on the foundational principle of aiming to accomplish program 
improvement through not one big change, but through a series of smaller changes, tested and implemented one 
at a time, that in the end have a cumulative effect.
Why use CQI? 
CQI takes a broader look at the systems in which programs or practices operate. Because of the pivotal role it 
plays in performance management, organizations implementing new clinical practices or programs for treating 
stimulant use disorders are encouraged to implement CQI procedures. 
What are the steps involved in CQI?
Although steps in the CQI process may vary based on objectives, typical CQI steps are:
•	 Identify a program or practice issue needing improvement and a target improvement goal
•	 Analyze the issue and its root causes
•	 Develop an action plan to correct the root causes of the problem, including specific actions to be taken
•	 Implement the actions in the action plan
•	 Review the results to confirm that the issue and its root causes have been addressed and short-term 
and long-term treatment outcomes have improved
•	 Repeat these steps to identify and address other issues as they arise
New Jersey Department of Children and Families (n.d.) CQI Framework. https://www.nj.gov/dcf/about/divisions/opma/CQI%20framework.pdf
Office of Adolescent Health (n.d.). Continuous Quality Improvement. https://www.hhs.gov/ash/oah/sites/default/files/cqi-intro.pdf 
Center for Health Enhancement Systems Studies, University of Wisconsin (n.d.) NIATx program https://www.niatx.net/what-is-niatx/ 
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Data collected as a part of any of the four evaluations are 
either quantitative or qualitative. 
Quantitative data are those collected in a numerical 
form which can be put into categories, or in rank order, 
or measured in units of measurement. These data can be 
processed by mathematical or statistical analysis. Types 
of quantitative data collection can include close-ended 
survey questions and polling responses.
Qualitative data, on the other hand, are any non-
numeric, text-based information such as verbal, visual, 
or written data. These types of data provide information 
about the acceptability of an intervention and the 
challenges recipients of the intervention face. Examples 
of qualitative data collection methods include interviews, 
focus groups, observations, gathering data from 
documents and images, and case studies.
One benefit of qualitative research is that it enables 
program managers, clinicians, and providers to learn from 
clients and to obtain the perspective of those with lived 
experiences.  It also can involve collecting data from staff 
who deliver treatment using the new practice to obtain 
their perspective on facilitators and challenges, or barriers, 
to practice implementation. Qualitative data can provide 
complementary context to quantitative data.
Outcomes
One of the final important but often challenging steps 
in the process of implementing practices is to determine 
whether they have yielded desired outcomes. An outcome 
is the change a program hopes to accomplish through the 
implementation of a practice. 
Below is a list of potential outcomes and illustrative 
outcome indicators and data sources that may be used to 
evaluate practices to reduce stimulant use disorders. Many 
of these short- and intermediate-term outcomes may be 
tracked at baseline and throughout the practice or program 
duration through an electronic health record. Longer-term 
outcomes may be obtained from administrative and survey 
data.
Outcome Illustrative Indicators Illustrative Data Sources
Process outcomes
Treatment retention Number of treatment sessions attended Attendance/administrative data 
Treatment engagement Extent of client engagement in the treatment Self-report
Short-term outcomes




Number of days/weeks without use
Longest duration of confirmed stimulant abstinence 
Total abstinence
Stimulant-negative urine drug 
screens
Self-report
Reduced craving Feeling of craving Self-report (e.g., Addiction Severity 
Index Scale) 
Standardized scales (e.g., Brief 
Substance Craving Scale)
Long-term individual- and population-level outcomes and impacts




Reduced prevalence of 
stimulant use 
Prevalence of stimulant use Large scale national surveys
Reduction in co-occurring 
mental health issues in 
individuals with substance 
use disorders
Prevalence of hospitalizations for mental health 
issues related to substance use disorders
Hospitals and medical facilities’ 
administrative data 
Reduction in substance use-
related crime 
Rates of substance use-related arrests Justice system administrative data
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Evaluation Resources 
Evaluating practice or program implementation
•	 A Framework for Program Evaluation from the 
Program Performance and Evaluation Office at 
CDC summarizes essential elements of program 
evaluation.
•	 Introduction to Program Evaluation for Public 
Health Programs is a self-study guide from 
CDC that includes worksheets and checklists for 
implementing the steps in CDC’s Framework for 
Program Evaluation.
•	 CDC’s Evaluation Brief provides information 
about document review and how it can be used 
for program evaluation. 
•	 HHS’s Administration for Families and Children’s 
webpage on evaluation provides multiple tools for 
prevention and treatment evaluation.
Evaluating client- and population-level outcomes
•	 National Science Foundation’s webpage on 
evaluation provides an overview of quantitative 
and qualitative data collection methods.  
•	 National Institute of Health’s webpage on 
evaluation provides information on engaging in 
qualitative research methods. 
Quality improvement and continuous 
performance monitoring
•	 Institute for Healthcare Improvement’s Quality 
Improvement Essentials Toolkit includes 
the tools and templates needed to launch a 
successful quality improvement project and 
manage performance improvement.
•	 The Network for Improvement of Addiction 
Treatment (NIATx)’s model of process improvement 
specifically for behavioral health care settings to 
improve access to and retention in treatment.
Resources for evaluating programs and 
practices in Native American communities
•	 Children’s Bureau’s A Roadmap for 
Collaborative and Effective Evaluation in 
Tribal Communities provides Native American 
values and priorities, knowledge of which can 
enhance trust between Tribal programs and their 
evaluation partners and other stakeholders.
•	 SAMHSA’s cultural card provides strategies to 
enhance cultural competence while providing 
services to American Indian and Alaska Native 
communities.
•	 Native American Motivational Interviewing: 
Weaving Native American and Western Practices 
is a manual for counselors in Native American 
communities.
•	 SAMHSA’s Behavioral Health Services for 
American Indians and Alaska Natives provides 
tips for providers to improve their cultural 
competence and provide culturally responsive, 
engaging, holistic, trauma-informed services to 
American Indian and Alaska Native clients.
•	 Children’s Bureau’s Creating a New Narrative: 
Collaborative and Effective Evaluation in 
Tribal Communities is a video that guides the 
development of culturally and scientifically 
rigorous evaluation.
•	 Native American Center for Excellence’s Steps 
for Conducting Research and Evaluation in 
Native Communities explores the lessons and 
challenges of research and evaluation in Native 
communities.
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The authors followed a rigorous, systematic evidence 
review process in the development of this guide. This 
appendix provides an overview of the evidence review 
methodology used to identify the ratings for the practices 
included in the guide; motivational interviewing, 
contingency management, community reinforcement 
approach, and cognitive behavioral therapy. Reviewers, in 
coordination with SAMHSA and experts, conducted a four 
step process to select practices, identify related studies, 
review and rate studies, and identify practice ratings.
Step 1: Practice  
Selection 
The authors identified these four practices after a review 
of the literature and in consultation with experts. In 
an effort to include interventions that would be most 
useful to those seeking to reduce stimulant use, eligible 
practices were required to meet the following criteria for 
evidence review: 
•	 Be clearly defined and replicable 
•	 Address the target outcome of reducing 
stimulant misuse 
•	 Be currently in use
•	 Have studies of their effectiveness
•	 Have accessible implementation and fidelity 
supports
At the conclusion of this step, SAMHSA and the guide’s 
Expert Panel reviewed the proposed practices identified 
by the authors and agreed on four for inclusion in the 
evidence review and rating process.
Step 2: Study 
Identification
Once the practices were selected, the reviewers 
conducted a comprehensive review of published 
research on these practices to identify studies of the 
selected practices. This review only included studies 
from eligible sources (i.e., peer reviewed journals and 
government reports) that avoid clear conflicts of interest. 
The reviewers documented all potential studies identified 
through the literature search.
The studies identified in the literature search varied in 
type and rigor, so the reviewers assessed them further for 
inclusion in the evidence review. To be eligible for review 
and study rating, research studies had to: 
•	 Employ a randomized or quasi-experimental 
design, or 
•	 Be a single sample pre-post design or 
an epidemiological study with a strong 
counterfactual—a study that analyzes what 
would have happened in the absence of the 
intervention. 
Literature reviews, descriptive studies, implementation 
studies, and meta-analyses were not included in the 
review, but were documented to provide context and 
identify implementation supports for the practices.
Additionally, to be eligible for further review and rating, 
studies had to:
•	 Be published or prepared in or after 2000
•	 Be publicly available peer-reviewed or research 
report
•	 Be available in English
•	 Include at least one eligible outcome related to 
reduced stimulant use
•	 Have a comparison/control group that is 
treatment as usual or no/minimal intervention 
if using a randomized experimental or quasi-
experimental designs
Step 3: Study Review  
and Rating
Next, trained reviewers assessed each study to ensure 
the methodology was rigorous and therefore could 
demonstrate causation between the practice and the 
identified outcomes. Reviewers reviewed and documented 
each study to ensure that: 
•	 Experimental and comparison groups were 
statistically equivalent, with the only difference 
being that participants in the experimental 
group received the intervention and those in the 
comparison group received treatment  as usual 
or no/minimal intervention 
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•	 For randomized experiments with high attrition 
and for quasi-experimental designs, baseline 
equivalence was established between the 
treatment and comparison groups 
•	 For randomized experiments, randomization 
was not compromised. For example, ensuring 
that reassignment of treatment status, usually 
made to balance the distribution of background 
variables between treatment and control groups, 
did not occur
•	 Study did not have any confounding factors 
(factors that affect the outcome but are not 
accounted for by the study)
•	 Missing data were addressed appropriately
o Imputation based on surrounding cases was 
considered valid 
o Complete case analysis was considered valid 
and accounted for as attrition 
o Using model with dummy for missing as a 
covariate was considered valid 
o Assuming all missing data points are either 
positive or negative was not considered 
valid 
o Regression-based imputation was consid-
ered valid, mean imputation was not consid-
ered valid.
•	 Outcome measures were reliable, valid, and 
collected consistently from all participants
•	 Valid statistical models were used to estimate 
impacts
•	 Practice demonstrated improved outcomes 
related to stimulant use
Based on the study design and these study characteristics, 
reviewers gave each study a rating for causal impact. 
Reviewers used the following scoring metric for each 
study based on the eight factors above to determine if a 
study is rated:
•	 High support of causal evidence
•	 Moderate support of causal evidence
•	 Low support of causal evidence
Only randomized controlled trials, quasi-experimental 
designs, and epidemiological studies with a strong 
comparison were eligible to receive a high or moderate 
study rating. 
Step 4: Practice Rating
After all studies for a practice were assessed for these 
criteria, the reviewers gave each practice a rating 
based on the number of studies with strong, moderate, 
or emerging support of causal impact. Causal impact is 
evidence demonstrating that an intervention causes, or 
is responsible for, the outcome measured in the study’s 
sample population. The practice was placed into one 
of the following categories based on the level of causal 
evidence of its studies:
•	 Strong Evidence: Causal impact demonstrated 
by at least two randomized controlled trials, 
quasi-experimental designs, or epidemiological 
studies with a high or moderate rating.
•	 Moderate Evidence: Causal impact 
demonstrated by at least one randomized 
controlled trial, quasi-experimental design, or 
epidemiological study with a high or moderate 
rating.
•	 Emerging Evidence: No study received a high 
or a moderate rating. The practice may have 
been evaluated with less rigorous studies (e.g., 
pre-post designs) that demonstrate an association 
between the practice and positive outcomes, but 
additional studies are needed to establish causal 
impact.
The four-step process described above resulted in 
identification and rating of four practices with strong 
evidence for reducing stimulant use. The rating given 
to each practice is intended to inform decision making 
about adoption of new practices or clinical or system 
enhancements that will improve outcomes for individuals 
with stimulant use disorders.
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